Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) shares surged Monday. The company recently announced the successful completion and early discontinuation of the Ibezapolstat Phase 2b trial for the treatment of C. difficile infection.
What To Know: Last Monday, Acurx announced that it has discontinued the Phase 2b clinical trial of ibezapolstat due to success. The company will analyze the data and report topline efficacy results which will allow Acurx to advance it to Phase 3 clinical trials more quickly.
Robert J. DeLuccia, Executive Chairman of Acurx, stated: “Considering the totality and weight of evidence of our preclinical, Phase 1 and Phase 2a clinical results and now with the observed aggregate blinded data, we determined it was in the best interests of the Company and its shareholders to discontinue the Phase 2b clinical trial early and prepare for Phase 3 clinical trials.”
“We look forward to compiling, analyzing the data and reporting topline results for the study’s primary clinical endpoint and safety aspects as soon as possible”. He further stated: “We thank the clinical trial investigators and patients across the country who participated in this study allowing advancement of this promising new antibiotic into late-stage clinical trials for this serious and life-threating infection which is classified by FDA and CDC as an urgent priority for which new classes of antibiotics are needed.”
Related Link: What’s Going On With V.F. Corporation Stock Today?
ACXP Price Action: Shares of ACXP were up 63.6% at $3.14 at the time of publication, according to Benzinga Pro.
Image by Pexels from Pixabay
